PharmaDiplomacy: A Proposal for a Collaborative, Mutually Acceptable Approach to Drug Pricing

OHE Lunchtime Seminar with James Anderson, GSK, Ri De Ridder, RIZIV-INAMI, and Sophia Tickell, Meteos.

The issue of pharmaceutical pricing and value is currently high on the agenda. In theory, generating consistent, comparable and reliable outcomes data around particular healthcare interventions should lead to a fair and objective assessment of their value, and competitive market forces should encourage price competition. In practice, of course, these remain highly challenging goals. 

This lunchtime seminar will debate whether and how systematic stakeholder discussion could support a more collaborative approach to pharmaceutical pricing that benefits payers, patients, healthcare providers and companies. Panelists will present and discuss the ‘Checklist for Collaborative, Mutually Acceptable Drug Pricing’, which is the output of the PharmaDiplomacy Dialogue, an EU/US leadership initiative, convened by Meteos and led by senior executives from across the health system.

The panel will be chaired by Nancy Devlin, Director of Research, OHE, and will include three members of the PharmaDiplomacy Dialogue, all of whom were involved in the development of the ‘Checklist’:
  • James Anderson, Head of Corporate Government Affairs, GlaxoSmithKline 
  • Ri De Ridder, Director, Belgian National Institute for Health and Disability Insurance (RIZIV-INAMI)
  • Sophia Tickell, Co-Founder & Partner, Meteos

View full seminar invite here:


Tuesday, 6 October 2015